Welcome to PREDICT Consortium

Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics

PREDICT will define the next generation of predictive biomarkers through the integration of clinical trial design with functional cancer genomics to enable personalised medicine and the cost-effective delivery of beneficial cancer therapeutics.

  • seventh-framework-programme
  • ocelot
  • sanger
  • predict-consortium-dna-strand
  • marsden
  • predict-consortium-lab
  • horizon

Results

Publications: 36

Conference talks given: 35

Data generation progress

Clinical samples collected (March 2014):

- A-PREDICT = 20 (expected by 06/2014 ~32)

- E-PREDICT = 29 (expected by 06/2014 = suspended to recruitment)

- NEO-RAD = 22 (expected by 06/2014 = 30)

RCC cell lines engineered: 18 (11 of established cell lines + 7 new from RCC-patient derived primary cell lines).

Latest News and Events

  • The final General Assembly will be held in Copenhagen on 18 December 2014¬† with a late dinner on De read more »
  • Launch of the G-2-O website. Genotype to Outcome is a web-server linking a selected mutation(s) to a read more »
  • Improved gene editing efficiencies using AAV- donors in¬†combination with nuclease based approaches. read more »

Software devlopment progress

Ocelot

PrediGO

Sequenza

predict-consortium-technician PREDICT is utilising whole genome RNA interference screens to identify which genes encoded by the cancer genome influence response to common cytotoxic and targeted therapeutics used in clinical practice.
predict-consortium-microscope PREDICT has initiated a series of single drug clinical trials in the pre-operative setting enabling tumour genomics analysis before and after treatment. The consortium is analysing clinical trial tumour tissue using whole genome sequencing and gene expression approaches in order to identify how tumour somatic mutations and gene expression changes evolve through therapy.
predict-consortium-technicians PREDICT is employing technological developments to develop new cancer models for in vivo and in vitro therapeutic assessments and utilising novel bioinformatics approaches to develop platforms for biomarker discovery.